• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄与心血管反应适应性。主要基于β受体阻滞剂和钙通道阻滞剂的降压治疗理念的决定因素。

Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers.

作者信息

Bühler F R

出版信息

Hypertension. 1983 Sep-Oct;5(5 Pt 2):III94-100.

PMID:6138311
Abstract

The patient's age has great impact on the development of hypertension, its duration, and severity. In patients with essential hypertension, sympathetic cardiovascular control changes from an early phase with increased beta-adrenoceptor-mediated responses, e.g., cardiac output and renin, into a later phase where these responses are blunted and alpha-adrenoceptor-mediated vasoconstriction prevails, associated with higher intracellular free sodium and calcium concentration. This pathophysiological view of essential hypertension has its corollary in the pharmacotherapeutic approach. Younger patients, who often have high renin levels, respond better to monotherapy with a beta-blocker or with a converting-enzyme inhibitor. Older patients, who often have low renin levels, respond less well to beta-blockers but particularly well to calcium entry blockers as an alternative to diuretics. Therefore, beta-blockers and calcium entry blockers form new cornerstones for antihypertensive treatment and strategy, with the potential of cardioprotection.

摘要

患者的年龄对高血压的发展、病程及严重程度有重大影响。在原发性高血压患者中,交感神经对心血管的控制从早期以β-肾上腺素能受体介导的反应增强(如心输出量和肾素增加)转变为后期这些反应减弱且以α-肾上腺素能受体介导的血管收缩为主,同时细胞内游离钠和钙浓度升高。原发性高血压的这种病理生理学观点在药物治疗方法中也有相应体现。年轻患者通常肾素水平较高,对β受体阻滞剂或转换酶抑制剂单一疗法反应较好。老年患者通常肾素水平较低,对β受体阻滞剂反应较差,但对作为利尿剂替代药物的钙通道阻滞剂反应特别好。因此,β受体阻滞剂和钙通道阻滞剂成为抗高血压治疗和策略的新基石,并具有心脏保护潜力。

相似文献

1
Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers.年龄与心血管反应适应性。主要基于β受体阻滞剂和钙通道阻滞剂的降压治疗理念的决定因素。
Hypertension. 1983 Sep-Oct;5(5 Pt 2):III94-100.
2
[Cardiovascular regulation as a function of age. Determinants of antihypertensive treatment based on beta-blockers and calcium inhibitors].[心血管调节与年龄的关系。基于β受体阻滞剂和钙拮抗剂的抗高血压治疗的决定因素]
Arch Mal Coeur Vaiss. 1985 Nov;78 Spec No:83-90.
3
Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients.肾素分析用于选择抗高血压基线药物。高肾素患者使用肾素抑制剂,低肾素患者使用钙通道阻滞剂。
Am J Med. 1984 Aug 20;77(2A):36-42.
4
Development and trends in the drug treatment of essential hypertension.原发性高血压药物治疗的进展与趋势
J Hypertens Suppl. 1992 Dec;10(7):S1-12.
5
Position of calcium antagonists in antihypertensive therapy.
J Cardiovasc Pharmacol. 1985;7 Suppl 4:S21-7. doi: 10.1097/00005344-198507004-00005.
6
Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry.抗高血压治疗趋势——来自以色列国家急性卒中(NASIS)登记处的经验教训。
Blood Press. 2014 Oct;23(5):262-9. doi: 10.3109/08037051.2013.876771. Epub 2014 Feb 3.
7
[Pharmacological basis of antihypertensive drug therapy].[抗高血压药物治疗的药理学基础]
Praxis (Bern 1994). 2004 May 12;93(20):847-56. doi: 10.1024/0369-8394.93.20.847.
8
Pressor responses to antihypertensive drug types.降压药类型引起的升压反应。
Am J Hypertens. 2010 Sep;23(9):1031-7. doi: 10.1038/ajh.2010.114. Epub 2010 Aug 19.
9
The case for beta-blockers as first-line antihypertensive therapy.β受体阻滞剂作为一线抗高血压治疗的依据。
J Hypertens Suppl. 1992 Jun;10(3):S21-7.
10
The place of the calcium antagonist verapamil in antihypertensive therapy.钙拮抗剂维拉帕米在抗高血压治疗中的地位。
J Cardiovasc Pharmacol. 1982;4 Suppl 3:S350-7.

引用本文的文献

1
Current drug treatment and treatment patterns with antihypertensive drugs.当前的药物治疗以及抗高血压药物的治疗模式。
Drugs. 1996 Jul;52(1):1-16. doi: 10.2165/00003495-199652010-00001.
2
Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy.伊拉地平缓释片治疗高血压左心室肥厚患者的疗效评估。
Cardiovasc Drugs Ther. 1994 Feb;8(1):153-60. doi: 10.1007/BF00877104.
3
Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
高血压和充血性心力衰竭患者对特定肾素-血管紧张素抑制剂的血流动力学反应。综述。
Drugs. 1984 Aug;28(2):144-69. doi: 10.2165/00003495-198428020-00004.
4
Angiotensin converting enzyme inhibitors and moderate hypertension.血管紧张素转换酶抑制剂与中度高血压
Drugs. 1990 Sep;40(3):326-45. doi: 10.2165/00003495-199040030-00002.
5
Physiological changes due to age. Implications for cardiovascular drug therapy.年龄引起的生理变化。对心血管药物治疗的影响。
Drugs Aging. 1991 Nov-Dec;1(6):467-76. doi: 10.2165/00002512-199101060-00006.
6
Ambulatory blood pressure monitoring in elderly hypertensives treated with the new calcium antagonist, nilvadipine.新型钙拮抗剂尼伐地平治疗老年高血压患者的动态血压监测
Eur J Clin Pharmacol. 1991;41(3):255-7. doi: 10.1007/BF00315439.